Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L. , Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L. and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, 128(23), pp. 2671-2682. (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (PMCID:PMC5146743)

[img]
Preview
Text
123758.pdf

798kB

Abstract

Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the possibility of discontinuing TKI treatment. We have previously reported that expression of the pivotal proinflammatory cytokine interleukin-1 (IL-1) is increased in CML bone marrow (BM). We show here that CML LSC demonstrated increased expression of the IL-1 receptors, IL-1RAP and IL- 1R1, and enhanced sensitivity to IL-1-induced NF-KB signaling compared to normal stem cells. Treatment with recombinant IL-1 receptor antagonist (IL-1RA) inhibited IL-1 signaling in CML LSC and inhibited growth of CML LSC. Importantly, the combination of IL-1RA with TKI resulted in significantly greater inhibition of CML LSC compared with TKI alone. Our studies also suggest that IL-1 signaling contributes to overexpression of inflammatory mediators in CML LSC, suggesting that blocking IL-1 signaling could modulate the inflammatory milieu. We conclude that IL-1 signaling contributes to maintenance of CML LSC following TKI treatment, and that IL- 1 blockade with IL-1RA enhances elimination of TKI-treated CML LSC. These results provide a strong rationale for further exploration of anti-IL-1 strategies to enhance LSC elimination in CML.

Item Type:Articles
Additional Information:This work was supported by National Institutes of Health, National Cancer Institute grant R01 CA172447, the Glasgow Experimental Cancer Medicine Centre, Bloodwise grant 14033, and Cancer Research-UK program grant C1107/A11008. V.L.C. is supported by the Wellcome Trust, the Scottish Translational Medicine, and Therapeutics Initiative (grant WT 085664) and by Clinical Research Fellowship Number 099710/X/12/Z.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Campbell, Dr Victoria and Jorgensen, Dr Heather and Hopcroft, Dr Lisa
Authors: Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., and Bhatia, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Blood
Publisher:American Society of Hematology
ISSN:0006-4971
ISSN (Online):1528-0020
Published Online:12 September 2016
Copyright Holders:Copyright © 2016 American Society of Hematology
First Published:First published in Blood 128(23):2671-2682
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
679891Targeting p53, cMyc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CMLTessa HolyoakeBloodwise (LLR)14033ICS - PAUL O'GORMAN LEUKAEMIA RESEARCH C
498551Key survival pathways in chronic myeloid leukaemia (cml) stem cells and novel approaches to their eradicationTessa HolyoakeCancer Research UK (CAN-RES-UK)11008RI CANCER SCIENCES
614931Wellcome Trust Scottish Translational Medicine and Therapeutics Initiative studentshipMhairi CoplandWellcome Trust (WELLCOME)099710/Z/12/ZICS - PAUL O'GORMAN LEUKAEMIA RESEARCH C